4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OL DIMERS AND RELATED COMPOUNDS

Abstract: The present invention relates to novel dimers of 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Description: 4,4-(Disubstituted)cycIohexan-l-ol Dimers and Related Compounds Field of Invention The present invention relates to novel 4.4-(disubstituted)cyclohexan-l-ol dimers and delated compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF). Background of the Invention Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli. Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease. One such way is by elevating levels of c AMP (adenosine cyclic 3\5'- monophosphate). Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta Medica, 17-29, 1973]. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg + 2-ATP to cAMP at an accelerated rate. Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocyte and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs). It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE) isozyme, PDE IV, is responsible for cAMP breakdown in airway smooth muscle and inflammatory cells. [Torphy, "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989]. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE TV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market. The compounds of this invention also inhibit the production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis. AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HTV). At least three types or strains of HTV have been identified, i.e., HTV- 1, HTV-2 and HTV-3. As a consequence of HTV infection, T-cell- mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HTV entry into the T lymphocyte requires T lymphocyte activation. Viruses such as HTV-1 or HTV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HTV gene expression and/or HTV replication. Cytokines, specifically TNF, are implicated in activated T-cell-mediated HTV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HTV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection. Monocytes, macTophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HTV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al, The Immunopathogenesis of HTV Infection, Advances in Immunology, Vol.57, 1989]. Mo-røkines, such as TNF, have been shown to activate HIV replication in monocytes and/or macrophages [See Poli et al., Proc. Natl. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells. TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted. TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al., Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al., Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al., Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991; and Luke et al., Journal of Infectious Diseases, 162:211-214,1990]. The ability to control the adverse effects of TNF is furthered by the use of the compounds which inhibit TNF in mammals who are in need of such use. There remains a need for compounds which are useful in treating TNF-mediated disease states which are exacerbated or caused by the excessive and/or unregulated production of TNF. Summary of the Invention The novel compounds of this invention are represented by Formula (I): wherein: \ is independently -(CR4R5) n C(O)O(CR4R5)rnR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5)nO(CR4R5) 6, or -(CR4 5 ) r 6 wherein the alkyl moieties may be unsubstituted or substituted with one or more fluorines; m is 0 to 2; n is 1 to 4; r is 0 to 6; R4 and R5 are independently selected from hydrogen or a C 1-2 al yl; R6 is independently hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCl-3 alkyl, indanyl, indenyl, C7.11 polycycloalkyl, teα^ydrofuranyl, furanyl, teα^ydropyranyl, pyrany tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3.6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety may be unsubstituted or substituted by 1 to 3 methyl groups, an ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyranyl, 2- tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-teuahydrofuranyl, or 2-te-rahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5)nO(CR4R5)mR6; X is independently YR2, fluorine, NR4R5, or foimyl amine; Y is independently O or S(O) m '; m' is a number having a value of 0, 1, or 2; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; X2 is independently O or NRg; X3 is independently hydrogen or X; R2 is independently selected from -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more fluorines; s is 0 to 4; Z is independently OR14, OR15, SR14, StO R?, S(O)2NRιoRl4, NR10R14. NRl4C(O)R9, NRιoC(Y')Rl4, NRi()C(O)OR7, NRiθC(Y')NRlθRl4, NRiθS(O)2NRiθRl4, N ioC(NCN)NRioRl4, NRiθS(O)2 7, NRιoC(CR4Nθ2)NRlθRl4, NRιoC(NCN)SR9, NRlθC(CR Nθ2)SR9, NRlθC(NRiO)NRlθRl4, NRiθC(O)C(O)NRlθRl4,or NRiθC(O)C(O)ORl4; Y' is independently O or S; R7 is -(CR4R5) q Rl2 or Ci.fi alkyl wherein the R12 or C\. alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO 2 , -NR 10 Rn, -C(O)R8, -CO2R8. -O(CH2)qR8. -CN, -C(O)NRιoRl l. -O(CH2)qC(O)NRιoRll, -O(CH2) q C(O)R9. -NRlθC(O)NRiθRιi, -NRιoC(O)Rn, -NRioC(O)OR9, -NRlθC(O)Ri3. -C(NRiθ)NRlθRl l, -C(NCN)NRιoRn, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRlθC(NCN)NRιoRιι, -NRιoS(O)2R9, -S(O)m'R9, -NRιoC(O)C(O)NRιoRl l, - NRlθC(O)C(O)Riθ, or R13; q is O, l, or 2; Rl2 is independently R13, C3-C7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2-imidazolyl), pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl; Rg is independently selected from hydrogen or R9; Ro is independently C1.4 alkyl unsubstituted or substituted by one to three fluorines; RlO is independently OR8 or Ri 1; Rj l is independently hydrogen, or C \_ alkyl unsubstituted or substituted by one to three fluorines; or when Rio and Ri 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S; Rl3 is independently oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cι_2 alkyl groups; Rl4 is independently hydrogen or R7; or when Rio and R14 are as NR10R14 they may together with the nitrogen form a 5 to 7 membered ring comprised only of carbon atoms or carbon atoms and at least one 1 heteroatom selected from O, N, or S; R15 is independently C(O)Rl4, C(O)NR4Rl4, S(O)2R7, or S(O)2NR4Ri4; or the pharmaceutically acceptable salts thereof. This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent The invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE IV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below. The invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I). The invention also provides a method for the treatment of asthma which comprises a-iministering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I). This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto. This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HTV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I). Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. In addition, compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo. Detailed Description of the Invention This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE TV in a mammal in need thereof and to inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I). Phosphodiesterase IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (I). Such viruses include, but are not limited to HTV-1, HTV-2 and HTV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex. This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HTV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I). The compounds of this invention may also be used in association with the veterinary treatment of animals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FIN) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses. The compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TΝF or will elicit TΝF production in vivo. A preferred disease state for treatment is fungal meningitis. Additionally, the compounds of Formula (I) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections. Drugs of choice for fungal infections, include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B. The compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fungal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment Preferably, a compound of Formula (I) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B. The term "C1.3 alkyl", "C^ alkyl", "C1.6 alkyl" or "alkyl" groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, rert-butyl, and the like. "Alkenyl" means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1 - propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl. The term "cycloalkyl" or "cycloalkyl alkyl" means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl. "Aryl" or "aralkyl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i.e, phenyl. The alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms. 'Ηeteroaryl" means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl. "Halo" means all halogens, i.e., chloro, fluoro, bromo, or iodo. "Inhibiting the production of IL-1" or "inhibiting the production of TΝF" means: a) a decrease of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of HL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event The phrase 'TNF mediated disease or disease states" means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as 'TNF" unless specifically delineated otherwise. Preferably TNF-α is inhibited. "Cytokine" means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them The cytokine inhibited by the present invention for use in the treatment of a HTV- infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and or (b) any cyto ine-mediated disease associated problem such as cachexia or muscle degeneration. Preferrably, his cytokine is TNF-α. All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE IV and in treatment of disease states mediated thereby. Preferred compounds are as follows: When Ri for the compounds of Formula (I) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluorines. The preferred halo- substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, - CHF2, -CF2CHF2, -CH2CF3, and -CH2CHF2. Preferred Ri substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl, C7.11 polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl unsubstituted or substituted by 1 or more fluorines, -(CH2)1-3C(O)O(CH2)0-2CH3, -(CH2)l-3θ(CH2)0-2CH3, and -(CH2)2-4θR When the Ri term is (CR4R5). the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5)n or (CR4R5)m; each repeating methylene unit is independent of the other, e.g., (CR4R5)n wherein n is 2 can be -CH2CH(-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can unsubstituted or be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above. When Ri is a C7-11 polycycloalkyl, examples are bicyclo[2.2.1]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2. l]octyl, tricyclo[S.2.1.0 2 t 6 ]decyl, etc. additional examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987. Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen. The preferred X2 group for Formula (I) is that wherein X2 is oxygen. The preferred X3 group for Formula (I) is that wherein X3 is hydrogen. Preferred R2 groups, where applicable, is a Ci-2 alkyl unsubstituted or substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a Ci-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties. W is preferably alkyl, alkenyl or alkynyl of 3 to 5 carbon atoms, and where it is alkenyl or alkynyl, that one or two double or triple bonds be present It is most preferred that W be 1,3-butadiynyl. Z is preferably OR14, OR15, SR14, S(O) m 'R7, S(O)2NRιoRl4, NR10 14, NRi4C(O)R9, NRiθC(O)Ri4, NRioC(O)OR7, NRiθC(O)NRiθRl4, NRlθS(O)2NRιoRl4, NRK)C(NCN)NRιoRl4, NRιoS(O)2R7, NRιoC(CR4Nθ2)NRιoRl4, NRlθC(NCN)SR9, NRιθC(CR4Nθ2)SR9, NRlθC(NRιo)NRιθRl4, NRioC(O)C(O)NRioRi4, or NRιoC(O)C(O)ORi4. Preferred R7 moieties include unsubstituted or substituted -(CH2)l- 2(cyclopropyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl), -(CH2)0- 2(cyclohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), (CH2)l.2(2-imidazolyl), (CH2)2(4- morpholinyl), (CH2)2(4-piperazinyl), (CH2) 1 -2(2-thienyl), (CH2) 1 -2(4-thiazolyl), and (CH2)0-2phenyl. Preferred rings when Rio and Ri 1 in the moiety -NRio l 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring unsubstituted or containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 2-(Rg)-l-imida--olyl, 1-pyrazolyl, 3- 8H -pyrazolyl, 1- triazolyl, 2-triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(Rg)-l-tetrazolyl, 5-(Rg)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-0*8H- piperazinyl, or pyirolyl ring. Preferred rings when Rg and R14 in the moiety -NRgRi4 together with the nitrogen to which they are attached may form a 5 to 7 membered ring unsubstituted or containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 1 -pyrazolyl, 1-triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl, morpholinyl, piperazinyl, and pyrrolyL The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but is not limited to, 2-(R7)-l-imidazolyl, 4-(R7)-l-imidazolyl, 5-(R7)-l-imidazolyl, 3-(R7)-l-pyrazolyl, 4-(R7)-l-pyrazolyl, 5-(R7)-l -pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l-triazolyl, 5-(R7)-l-triazolyl, 5-(R7)-l-tetrazolyl, and 5-0^7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-0*7)- 1-tetrazolyl, 4-(R7)-l- piperazinyl. Where applicable, the ring may be substituted one or more times by R7. Preferred groups for NR8R14 which contain a heterocyclic ring are 5-(R 14)- 1- tetrazolyl, 2-0^14)-l-imidazolyl, 5-(Ri4)-2-tetrazolyl, 4-0*14)-l-piperazinyl, or 4-03.15)- 1 -piperazinyl. Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[l,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[ 1,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl). When the R7 group is unsubstituted or substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be unsubstituted or substituted by Rg either on an available nitrogen or carbon atom, such as l-(R8)-2-imidazolyl, l-0 g)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(Rg)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(Rg)-4-triazolyl, or l-(R8)-5-triazolyl. Where applicable, the ring may be substituted one or more times by Rg. Preferred arc those compounds of Formula (I) wherein R is -CH2-cyclopropyl, -CH2-C5-6 cycloalkyl, -C4.6 cycloalkyl with or without a ring hydroxyl substitution, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Ci-2 alkyl unsubstituted or substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro- substituted alkyl and X is YR2- Most preferred are those compounds wherein Ri is -CH2-cyclopropyl, -CH2-3- hydroxycyclopropyl, cyclopentyl, 3-hydroxycyclopenryl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; R2 is CF2H or methyl, and W is 1,3- butadiynyl. It will be recognized that some of the compounds of Formula (I) may exist in both racemic and optically active forms; some may also exist in distinct diastereomeric forms possessing distinct physical and biological properties. All of these compounds are considered to be within the scope of the present invention. Pharmaceutically acceptable salts of the instant compounds, where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases. Pharmaceutically acceptable salts are prepared in a standard manner. The parent compound, dissolved in a suitable solvent, is treated with an excess of an organic or inorganic acid, in the case of acid addition salts of a base, or an excess of organic or inorganic base where the molecule contains a COOH for example. Pharmaceutical compositions of the present invention comprise a pharmaceutical carrier or diluent and some amount of a compound of Formula (I). The compound may be present in an amount to effect a physiological response, or it may be present in a lesser amount such that the user will need to take two or more units of the composition to effect the treatment intended. These compositions may be made up as a solid, liquid or in a gaseous form. Or one of these three forms may be transformed to another at the time of being administered such as when a solid is delivered by aerosol means, or when a liquid is delivered as a spray or aerosol. The nature of the composition and the pharmaceutical carrier or diluent will, of course, depend upon the intended route of administration, for example parenterally, topically, orally or by inhalation. For topical administration the pharmaceutical composition will be in the form of a cream, ointment liniment, lotion, pastes, aerosols, and drops suitable for administration to the skin, eye, ear, or nose. For parenteral administration the pharmaceutical composition will be in the form of a sterile injectable liquid such as an ampule or an aqueous or non-aqueous liquid suspension. For oral administration the pharmaceutical composition will be in the form of a tablet, capsule, powder, pellet, atroche, lozenge, syrup, liquid, or emulsion. When the pharmaceutical composition is employed in the form of a solution or suspension, examples of appropriate pharmaceutical carriers or diluents include: for aqueous systems, water, for non-aqueous systems, ethanol, glycerin, propylene glycol, com oil, cottonseed oil, peanut oil, sesame oil, liquid parafins and mixtures thereof with water, for solid systems, lactose, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide. Also, in addition to the pharmaceutical carrier or diluent, the instant compositions may include other ingredients such as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers and the like, provided that the additional ingredients do not have a detrimental effect on the therapeutic action of the instant compositions. The pharmaceutical preparations thus described are made following the conventional techniques of the pharmaceutical chemist as appropriate to the desired end product In these compositions, the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient. When the diluent is a solid it may be present in lesser, equal or greater amounts than the solid active ingredient Usually a compound of formula I is administered to a subject in a composition comprising a nontoxic amount sufficient to produce an inhibition of the symptoms of a disease in which leukotrienes are a factor. Topical formulations will contain between about 0.01 to 5.0% by weight of the active ingredient and will be applied as required as a preventative or curative agent to the affected area. When employed as an oral, or other ingested or injected regimen, the dosage of the composition is selected from the range of from 50 mg to 1000 mg of active ingredient for each administration. For convenience, equal doses will be administered 1 to 5 times daily with the daily dosage regimen being selected from about 50 mg to about 5000 mg. No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention. Methods Of Preparation Synthetic Scheme(s) With Textual Description Compounds of Formula (I), wherein W is a 1,3-butadiyne and wherein A and B represent Z as defined in relation to Formula (I) or a group convertible to Z, may be prepared by the processes disclosed herein which comprise, for example, coupling of a molecule of Formula }- Scheme 1 with a molecule of Formula 2, -Scheme 1 using an appropriate metal salt, such as cupric acetate, in a suitable solvent, such as DMF or pyridine, or a combination, such as pyridine/methanol/water, as in the method of Eglington and Galbraith (7. Chem. Soc, 1959, 889), to provide a compound of Formula 3- Scheme 1. Compounds of the Formula 1- Scheme 1 may be prepared by procedures analogous to those described in PCT application number PCT/US93/02516 published as WIPO publication number WO 93/19751. Schema 1 a) Cu(OAc ) 2 *H 2 O. DMF or C 5 H 5 N Reduction of a compound of Formula (I), wherein W is a 1 ,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z to a compound of Formula (I) wherein W is a fully saturated hydrocarbon chain (i.e., n-butyl) may be accomplished using, e.g., palladium metal according to the method of Tedeschi (J. Org. Chem., 1962, 27, 2398), or, e.g., platinum oxide according to the method of Jutz (Ber., 1958, 91, 1867) or that of Suzuki and Kurosawa (Chem. Lett., 1980, 1177). Reduction of a compound of Formula (I), wherein W is a 1,3-butadiyne and wherein Z represents Z as defined in relation to Formula (I) or a group convertible to Z, to provide a compound of Formula (I) wherein W is a 1,3-butadiene may be accomplished using, e.g., the hydroboration-protonolysis procedure of Zweifel and Polston (J. Am. Chem. Soc., 1970, 92, 4068), or, e.g., the hydroalumination- protonolysis procedure of Zweifel et al. (Synthesis, 1977, 52). Alternatively, compounds of Formula (1), wherein W and Z represent W and Z as defined in relation to Formula (I) or a group convertible to W or Z, may be prepared from the corresponding ketones as, e.g., compound 1 -Scheme 2. by the synthetic procedures described in copending U.S. patent application filed on even day herewith by the same assignee and identified as P50285. Schema 2 Depending upon the exact nature of the Z groups of the compounds of the Formula (I), the Z groups may require protection during the coupling and/or reductive steps described herein, followed by deprotection, to provide the Formula (I) compound. Such protective groups are well known to those skilled in the art. (See: Greene, T. and Wuts, P.G.M., Protecting Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons, New York, 1991.) Compounds where Z is a group other than -OH can be prepared by methods known in the an and in particular by manipulation of the -OH. Such methods are described in PCT application serial number PCT/US93/02516 published 14 October 1993 as WIPO number WO 93/19751. Preparation of the remaining compounds of Formula (I) may be accomplished by procedures analogous to those described above and in the Examples, infra. Compounds of Formula (I) wherein Z is OH may be interconvened using the standard alcohol inversion procedures known in the art It will be recognized that compounds of Formula (I) may exist in two distinct diastereomeric forms possessing distinct physical and biological properties; such isomers may be separated by standard chromatographic methods. Such isomers may be independently convened to the remaining compounds of Formula (I) wherein Z is other than OH, SH, and NH2 by any of the wide variety of O, S, and N alkylation, sulfamidation, imidation, oxidation, or acylation procedures known to those of skill in the an. It will be recognized that compounds of Formula (I) may exist in distinct diastereomeric forms possessing distinct physical and biological properties; such isomers may be separated by standard chromatographic methods. The following examples are given to further illustrate the described invention. These examples are intented solely for illustrating the invention and should not be read to limit the invention in any manner. Reference is made to the claims for what is reserved to the inventors hereunder. Experimentals Example l Preparation of 1.4-to-(rc-4-(3-cvclopen-vloxv-4-methoxvphenvIVr-l-cvclohexanoll- 4-y-lb--ta-l.3-di.yng la) -r_v_- 4-(3-cyclcpentyloxy-4-meiΛoxypι e^ and cis- [4-(3-cyclopentyloxy-4-methoxyphenyl)-4-ethynylcyclohexan- 1 -ol] To a solution of 4-(3-cyclopenryloxy^nκthoxyphenyl)-4-ethynylcyclohexan- 1 - one (0.34 g, 1.1 mmol, prepared as described in PCT application number PCT/US93/01990 published 14 October 1993 as WIPO number WO 93/19748) in 1,2- dimethoxyethane (5 mL) under an argon atmosphere was added sodium borohydride (0.08 g, 2.2 mmol) and the mixture was stirred at room temperature for 0.5 h. Water was added, the mixture was extracted three times with dichloromethane, was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 3:7 ethyl acetate :hexanes, provided -rαΛ?-[4-(3-cyclopentyloxy-4-methoxyphenyl)- 4-ethynylcyclohexan-l-ol] (described in U. S. Patent application PCT application numbers PCT/US93 02325 and PCT/US93/02516 (WIPO publication numbers WO 93/19750 and WO 93/197 1 respectively, both pubUshed 14 October 1993 as αr-[4-(3- cyclopentyloxy-4-methoxyphenyl)-4-ethynylcyclohexan-l-ol]) as a wax *H-NMR (400 MHz, CDC13) 67.14 (d, J=2.3 Hz, 1H), 7.04 (dd, J=8.5, 2.3 Hz, 1H), 6.82 (d, J=8.5 Hz, 1H), 4.79 (m, 1H), 3.83 (s, 3H), 3.68 (m, 1H), 2.46 (s, 1H), 1.7 - 2.1 (m, 14H), 1.6 (m, 2H). cύ-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-ethynylcyclohexan- 1 -ol] also was isolated from this procedure as a colorless oil. H-NMR (400 MHz, CDCI3) δ 7.17 (d, J=1.9 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 6.84 (d, J=8.4 Hz, 1H), 4.80 (m, 1H), 4.13 (br s, 1H), 3.84 (s, 3H), 2.38 (s, 1H), 2.15 (m, 4H), 1.7 - 2.0 (m, 10H), 1.75 (m, 2H). 1 b) 1 ,4-bis- [ [c-4-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1 -cyclohexanol]-4-yl } buta- 1,3-diyne A mixture of trαΛ-f-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4- ethynylcyclohexan-1-ol] (0.25 g, 0.81 mmol) and copper acetate monohydrate (0.49 g, 2.42 mmol) in dimethyl formamide (10 mL) under an argon atmosphere was heated at 65-70°C for 0.5 h, then was cooled. Water was added, the mixture was extracted twice with ethyl acetate, the combined organic extract was washed three times with water, once with brine, was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 1:1 ethyl acetate :hexanes, provided 1 ,4-bis- { [c-4-(3-cyclopentyloxy-4-memoxyphenyl)-r-l-cyclohexanol]-4-yl]buta-l ,3- diyne as a white solid, mp 79 - 80°C. Anal. (C40H50O6 O.5 H2O) calcd: C, 75.56; H, 8.08; found: C, 75.42; H, 8.35. Example 2 Preparation of 1.4-to-(rt-4-(3-cvclopen loxv-4-methoxvphenvlVr-l-cvclohexanoπ-4- A mixture of ci5-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-ethynylcyclohexan- l-ol] (0.02 g, 0.07 mmol) and copper acetate monohydrate (0.04 g, 0.20 mmol) in dimethyl formamide (2 mL) under an argon atmosphere was heated at 65-70°C for 2.5 h, then was cooled. Water was added, the mixture was extracted twice with ethyl acetate, the combined organic extract was washed three times with water, once with brine, was dried (magnesium sulfate) and was evaporated. Purification by flash chromatography, eluting with 1:1 ethyl acetate:hexanes, provided l,4-/_w-{[r-4-(3- cyclopentyloxy-4-methoxyphenyl)-r- 1 -cyclohexanol]-4-yl } buta- 1 ,3-diyne as a yellow foam, mp 63-66°C. Anal. (C40H50O6 I.6 H2O) calcd: C, 73.28; H, 8.18; found: C, 73.64; H, 8.59. Similarly the other compounds of Formula I can be prepared by proceeding in a similar manner as described above by simply substituting for the intermediates named in Examples 1 and 2, the other appropriate intermediates needed to make the other compounds of Formula I. UTILITY EXAMPLES EXAMPLE A Inhibitory ef ect of compounds of Formula (I) on in vitro TNF production by human monocytes The inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al., EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990. EXAMPLE B Two models of endotoxic shock have been utilized to determine in vivo TNF activity for the compounds of Formula (I). The protocol used in these models is described in Badger et al., EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990. The compound of Example 1 herein demonstrated a positive in vivo response in reducing serum levels of TNF induced by the injection of endotoxin. EXAMPLE C Isolation of PDE Isozymes The phosphodiesterase inhibitory activity and selectivity of the compounds of Formula (I) can be determined using a battery of five distinct PDE isozymes. The tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE Ic, guinea-pig heart; 3) PDE HI, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la"), canine trachealis. PDEs la, lb, Ic and UJ are partially purified using standard chromatographic techniques [Torphy and Cieslinslri, Mol. Pharmacol., 37:206-214, 1990]. PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-Sepharose chromatography [Torphy et al, J. Biol. Chem., 267:1798-1804, 1992]. Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive IC50's in the nanomolar to μM range for compounds of the workings examples described herein for Formula (I) have been demonstrated.

Claims: What is claimed is: 1. wherein: Ri is independently -(CR4R5)nC(O)O(CR4R5)mR6. -(CR4R5)nC(O)NR4(CR4R5)mR6, -(CR4R5) n O(CR4R5)m 6, or -(CR4Rs)r 6 wherein the alkyl moieties may be unsubstituted or substituted with one or more fluorines; m is 0 to 2; n is 1 to 4; r is 0 to 6; R4 and R5 are independently selected from hydrogen or a Ci-2 alkyl; R6 is independently hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, teff-ihydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3.6 cycloalkyl, or a C4- 6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety may be unsubstituted or substituted by 1 to 3 methyl groups, an ethyl group, or an hydroxyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R6 is 2-tetrahydropyτanyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in -(CR4R5)nO(CR4R5)mR6; X is independently YR2, fluorine, NR4R5, or formyl amine; Y is independently O or S(O) m '; m' is a number having a value of 0, 1, or 2; W is alkyl of 2 to 6 carbons, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms; X2 is independently O or NRg; X3 is independently hydrogen or X; R2 is independently selected from -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more fluorines; s is 0 to 4; Z is independently OR14, OR15, SR14, S(O) m 'R7, S(O)2NRιoRl4, NR10R14, NRi4C(O)R9, NRioC(Y')Rl4, NRιoC(O)OR7, NRioC(Y')NRi()Rl4, NRlθS(O)2NRιoRl4, NRioC(NCN NRioRi4, NRιoS(O)2R7, NRloC(CR4Nθ2)NRioRl4, N ιoC(NCN)SR9, NRlθC(CR4Nθ2)SR9, NRlθC(NRlθ)NRlθRl4, NRlθC(O)C(O)NRiθRl4,or NRιoC(O)C(O)ORl4; Y' is independently O or S; R7 is - CR4R5)qRi2 or C\. alkyl wherein the R12 or Cι_6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -F, -Br, -Cl, -NO2, -NR QRI 1, -C(O)R8, -CO2R8, -O(CH 2 )qR8. -CN, -C(O)NRiθRl l, -O(CH 2 )qC(O)NRiθRl l, -O(CH 2 ) q C(O)R9, -NRloC(O)NRιoRl l, -NRιoC(O)Rn, -NRιoC(O)OR9, -NRlθC(O)Ri3, -C(NRιo)NRlθRll, -C(NCN)NRιoRl l, -C(NCN)SR9, -NRιoC(NCN SR9 , -NRιoC(NCN)NRιoRl l, -NRιoS(O)2R9, -S(O) m 'R9, -NRιoC(O)C(O)NRιoRl l, - NRιoC(O)C(O)Rιθ, or R13; q is O, l, or 2; Rl2 is independently R13, (CH2)q, C3-C7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, ( 1 - or 2-imidazolyl), pyrrolyl, piperazinyl, pipcridinyl, morpholinyl, furanyl, (2- or 3-thienyl), quinolinyl, naphthyl, or phenyl; Rg is independently selected from hydrogen or R9; R9 is independently C1.4 alkyl unsubstituted or substituted by one to three fluorines; R 10 is independently OR8 or R 11 ; R 1 is independently hydrogen, or C1.4 alkyl unsubstituted or substituted by one to three fluorines; or when Rio and Rl 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S; R 13 is independently oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cj.2 alkyl groups; Rl4 is independently hydrogen or R7; or when Rio and R14 are as NRiθRl4 they may together with the nitrogen form a 5 to 7 membered ring comprised only of carbon atoms or carbon atoms and at least one 1 heteroatom selected from O, N, or S; Rl5 is independently C(O)Ru, C(O)NR4Ri4, S(O)2R7, or S(O)2NR4Rl4; or the pharmaceutically acceptable salts thereof. 2. A compound according to claim 1 wherein Ri is -CH2-cyclopropyl, -CH2-3-hydroxycyclopropyl, cyclopentyl, 3-hydroxycyclopcntyl, methyl or CF2H; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; R2 is CF2H or methyl, and W is 1,3- butadiynyl. 3. A compound according to claim 2 which is 1 ,4-bis- [ [c-4-(3- cyclopentyloxy-4-methoxyphenyl)-r-l-cyclohexanol]-4-yl)buta-l,3-diyne_ or 1,4-føs- { [ j * -4-(3-cyclopentyloxy-4-methoxyphenyl)-r- 1 -cyclohexanol]-4-yl } buta- 1 ,3-diyne, or a pharmaceutically acceptable salt hereof. 4. A pharmaceutical composition comprising a compound of Formula I according to claims 1 and a pharmaceutically acceptable excipient

Inventors: CHRISTENSEN SIEGFRIED B IV, KARPINSKI JOSEPH M, CHRISTENSEN, SIEGFRIED, B., IV, KARPINSKI, JOSEPH, M.
Applicants: CHRISTENSEN SIEGFRIED B IV, KARPINSKI JOSEPH M, SMITHKLINE BEECHAM CORP, CHRISTENSEN, SIEGFRIED, B., IV, KARPINSKI, JOSEPH, M., SMITHKLINE BEECHAM CORPORATION
Application year: 1995
Main classification: C07C229
IPC codes: A61K31, A61P29, A61P37, A61P43, C07C43, H04L25